In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
When the board of The Boston Trust & Walden Funds "experimented" with a virtual meeting in February, independent Chairman Michael Van Buskirk and the other directors ...
Mutual fund boards may decide to conduct their meetings telephonically over the next few months rather than risk directors being exposed to the fast-spreading coronavirus, or ...
In his new role heading up Independent Directors Council, Thomas Kim plans to focus on the group's core mission while expanding its presence and influence. "As ...
In late November 2019, the Securities and Exchange Commission checked another item off its ambitious rulemaking agenda with a rule proposal involving one of the more ...